ABSTRACT
Intramolecular endo-cyclization reactions of N-acyliminium ions have seen wide application for the synthesis of heterocyclic compounds. The corresponding exocyclic variant, which would provide 1-aminotetralin derivatives, for example, has little precedent. We have discovered that acyclic N-acylcarbamates can be readily reduced to the corresponding N-acylhemiaminal derivatives in high yield using DIBAL as the reducing agent. These intermediates are remarkably stable and, if desired, can be purified and stored. The acyclic N-acylhemiaminals undergo both intra- and intermolecular nucleophilic addition reactions mediated by strong Lewis acids, such as TiCl(4). Diastereoselectivity, induced either by a substituent on the newly formed ring, or by utilizing a chiral ester on the carbamic acid, was disappointingly low. This methodology was successfully applied to the synthesis of the racemic form of the marketed antidepressant sertraline.
Subject(s)
Antidepressive Agents/chemical synthesis , Selective Serotonin Reuptake Inhibitors/chemical synthesis , Sertraline/chemical synthesis , Imines/chemistry , Tetrahydronaphthalenes/chemistryABSTRACT
The hypocholesterolemic activities of pamaqueside and tiqueside, two structurally similar saponins, were evaluated in cholesterol-fed rabbits. The pharmacological profiles of the saponins were virtually identical: both dose-dependently decreased the intestinal absorption of labeled cholesterol 25-75%, increased fecal neutral sterol excretion up to 2.5-fold, and decreased hepatic cholesterol content 10-55%. High doses of pamaqueside (>5 mg/kg) or tiqueside (>125 mg/kg) completely prevented hypercholesterolemia. Decreases in plasma and hepatic cholesterol levels were strongly correlated with increased neutral sterol excretion. Ratios of neutral sterol excreted to pamaqueside administered were greater than 1:1 at all doses, in opposition to the formation of a stoichiometric complex previously suggested for tiqueside and other saponins. Ratios in tiqueside-treated rabbits were less than unity, a reflection of its lower potency. Pamaqueside-treated rabbits exhibited a more rapid decline in plasma cholesterol concentrations than control animals fed a cholesterol-free diet, indicating that the compound also inhibited the absorption of biliary cholesterol. Intravenous administration of pamaqueside had no effect on plasma cholesterol levels despite plasma levels twice those observed in rabbits given pamaqueside orally. These data indicate that pamaqueside and tiqueside induce hypocholesterolemia by blocking lumenal cholesterol absorption via a mechanism that apparently differs from the stoichiometric complexation of cholesterol hypothesized for other saponins.
Subject(s)
Cholesterol, Dietary/metabolism , Intestinal Absorption/drug effects , Saponins/pharmacology , Administration, Oral , Animals , Anticholesteremic Agents/pharmacology , Bile/metabolism , Cholesterol/blood , Cholesterol, HDL/blood , Feces/chemistry , Hypercholesterolemia/metabolism , Injections, Intravenous , Liver/metabolism , Male , Molecular Structure , Rabbits , Sterols/analysisABSTRACT
Cholesterol absorption inhibition remains an attractive approach for the treatment of hypercholesterolemia. We have continued our SAR development in the spirostanyl cellobioside class of agents seeking a greater understanding of the role carbamoyl substitution has on the potency in this series. In this regard, a series of differentially substituted carbamate analogs were made with and without deoxygenations. From this study, it was determined that the minimal requirements for optimal potency was a lone carbamate at C4" and deoxygenation at the C6" position.
Subject(s)
Anticholesteremic Agents/chemistry , Cellobiose/chemistry , Spirostans/chemistry , Anticholesteremic Agents/pharmacology , Cellobiose/pharmacology , Molecular Structure , Structure-Activity RelationshipABSTRACT
We have explored the use of steroidal glycosides as cholesterol absorption inhibitors which act through an unknown mechanism. The lead for this program was tigogenin cellobioside (1, tiqueside) which is a weak inhibitor (ED50 = 60 mg/kg) as measured in an acute hamster cholesterol absorption assay. Modification of the steroid portion of the molecule led to the discovery of 11-ketotigogenin cellobioside (5, pamaqueside) which has an ED50 of 2 mg/kg. Replacement of the cellobiose with other sugars failed to provide more potent analogs. However, large improvements in potency were realized through modification of the hydroxyl groups on the cellobiose. This strategy ultimately led to the 4", 6"-bis[(2-fluorophenyl)carbamoyl]-beta-D-cellobiosyl derivative of 11-ketotigogenin (51) with an ED50 of 0.025 mg/kg in the hamster assay, as well as the corresponding hecogenin analog 64 (ED50 = 0.07 mg/kg).
Subject(s)
Cholesterol/pharmacokinetics , Hypolipidemic Agents/chemistry , Saponins/chemistry , Absorption/drug effects , Animals , Cricetinae , Drug Design , Hypolipidemic Agents/pharmacology , Liver/drug effects , Liver/metabolism , Models, Chemical , Saponins/pharmacology , Structure-Activity RelationshipSubject(s)
Hypolipidemic Agents/pharmacology , Saponins/pharmacology , Animals , Carbohydrate Sequence , Cholesterol, Dietary/administration & dosage , Cricetinae , Hypolipidemic Agents/chemistry , Hypolipidemic Agents/pharmacokinetics , Molecular Sequence Data , Saponins/chemistry , Saponins/pharmacokineticsABSTRACT
A-77636, ((1R,3S) 3-(1'-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benz opyran hydrochloride), is a selective dopamine D1 receptor agonist. In a battery of receptor binding assays, A-77636 shows the highest affinity (pKi = 7.40 +/- 0.09; Ki = 39.8 nM) for the dopamine D1 receptor. A-77636 is an agonist at the dopamine D1 receptors in the fish retina (pEC50 = 8.13; EC50 = 1.1 nM; intrinsic activity = 102% of dopamine) and the rat caudate-putamen (pEC50 = 8.97; intrinsic activity = 134% of dopamine). The compound is functionally inactive at dopamine D2 receptors (EC50 > 10 microM). In rats with unilateral 6-OHDA (6-hydroxydopamine) lesions of the nigro-striatal dopaminergic pathway, A-77636 elicits prolonged (> 20 h) contralateral turning that is blocked by SCH 23390, a D1 receptor antagonist, but not by haloperidol at doses selective for the dopamine D2 receptor. Higher doses of A-77636 produce forelimb clonus in rats and mice. When tested in marmosets treated with MPTP to induce a parkinsonian-like state, A-77636 increases locomotor activity and decreases the severity of the parkinsonian-like symptoms: the compound is active after either subcutaneous or oral administration. A-77641, the optical antipode of A-77636, has a lower affinity towards the dopamine D1 receptor (pKi = 5.14, Ki = 7200 nM), is less potent as a dopamine D1 receptor agonist (pEC50 = 5.65; EC50 = 2200 nM), fails to elicit turning in the 6-OHDA-lesioned rat, and lacks antiparkinsonian efficacy in the MPTP-treated marmoset.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Adamantane/analogs & derivatives , Antiparkinson Agents/pharmacology , Benzopyrans/pharmacology , Dopamine Agents/pharmacology , Parkinson Disease, Secondary/drug therapy , Receptors, Dopamine D1/metabolism , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology , Adamantane/administration & dosage , Adamantane/metabolism , Adamantane/pharmacology , Administration, Oral , Animals , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/metabolism , Benzazepines/pharmacology , Benzopyrans/administration & dosage , Benzopyrans/metabolism , Binding Sites , Callithrix , Cell Line , Dopamine Agents/administration & dosage , Dopamine Agents/metabolism , Fishes , Injections, Subcutaneous , Mice , Motor Activity/drug effects , Oxidopamine/pharmacology , Parkinson Disease, Secondary/chemically induced , Rats , Receptors, Dopamine D1/drug effectsABSTRACT
A68930, [1R, 3S] 1-aminomethyl-5,6-dihydroxy-3-phenylisochroman HCl, is a potent, partial agonist in the dopamine-sensitive adenylate cyclase model of the D1 dopamine receptor in fish retina. In the rat caudate-putamen model of the D1 dopamine receptor, A68930 is a potent (EC50 2.1 nM) full agonist. In contrast, A68930 is a much weaker (EC50 = 3,920 nM) full agonist in a biochemical model of the D2 dopamine receptor. A68930 also displays weak 2 agonist activity but the molecule is virtually inactive at the 1 and beta-adrenoceptors. When tested in rats bearing a unilateral 6-OHDA lesion of the nigro-neostriatal neurons, A68930 elicits prolonged (> 20 hr) contralateral turning.
Subject(s)
Chromans/pharmacology , Dopamine Agonists/pharmacology , Receptors, Dopamine D1/agonists , Adenylyl Cyclases/metabolism , Animals , Behavior, Animal/drug effects , Carps , Caudate Nucleus/enzymology , Enzyme Activation/drug effects , Putamen/enzymology , Rats , Retina/metabolism , Seizures/chemically inducedABSTRACT
The synthesis and dopaminergic activity of a series of C3 and nitrogen-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans (isochromans) is described. The synthesis of the compounds was stereospecific for the 1,3 cis isomer, and the enantioselective synthesis of both enantiomers of one of the analogues (20) was achieved. It was determined that all of the dopaminergic activity resides in the [1R,3S] isomer. Generally, substitution at the C3 position provided compounds with very high potency (less than 10 nm EC50) and selectivity for the D1 receptor, with a wide range of intrinsic activities (60-160%). Analogues containing C3 substituents including aryl, arylalkyl, and cyclic and acyclic alkyl groups showed a marked enhancement of dopaminergic activity compared to the unsubstituted compound. As a class, the drugs were orally active in the rat rotation model with a very long duration of action.
Subject(s)
Chromans/chemical synthesis , Receptors, Dopamine/metabolism , Adenylyl Cyclases/metabolism , Animals , Binding Sites , Binding, Competitive , Carps , Chemical Phenomena , Chemistry , Chromans/metabolism , Chromans/pharmacology , Colforsin/pharmacology , Corpus Striatum/metabolism , Cyclic AMP/biosynthesis , Molecular Structure , Motor Activity/drug effects , Pituitary Neoplasms/metabolism , Rats , Receptors, Dopamine D1 , Receptors, Dopamine D2 , Rotation , Stereoisomerism , Structure-Activity Relationship , Tumor Cells, CulturedABSTRACT
A68930, (1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman HCl, is a potent (EC50 = 2.5 nM), partial (intrinsic activity = 66% of dopamine) agonist in the fish retina dopamine-sensitive adenylate cyclase model of the D1 dopamine receptor. In the rat caudate-putamen model of the D1 dopamine receptor, A68930 is a potent (EC50 = 2.1 nM) full agonist. In contrast, A68930 is a much weaker (EC50 = 3920 nM) full agonist in a biochemical model of the dopamine D2 receptor. The orientation of the 3-phenyl substituent in the molecule is critical for the affinity and selectivity of the molecule towards the dopamine D1 receptor. A68930 also displays weak alpha 2-agonist activity but the molecule is virtually inactive at the alpha 1- and beta-adrenoceptors. When tested in rats bearing a unilateral 6-OHDA lesion of the nigro-neostriatal neurons, A68930 elicits prolonged (greater than 20 h) contralateral turning that is antagonized by dopamine D1 receptor selective doses of SCH 23390 but not by D2 receptor selective doses of haloperidol. In this lesioned rat model, A68930 increases 2-deoxyglucose accumulation in the lesioned substantia nigra, pars reticulata. When tested in normal rats, A68930 elicits hyperactivity and, at higher doses, produces a forelimb clonus.